More Australians than ever are turning to injectable weight loss medication, with recent data showing approximately 500,000 monthly users. Of these, nearly half are paying out-of-pocket, with monthly costs ranging from $200 to $600. This growing use is likely to influence both healthcare and pharmaceutical markets, while also sparking debate about accessibility, cost and long-term safety.
These drugs, known as GLP-1 medications, have experienced rapid sales growth since 2020. Frequently promoted by celebrities and social media influencers, products like Ozempic and Mounjaro are now widely recognised. Initially developed to treat type 2 diabetes, they are increasingly being used off-label for weight loss. Researchers from a leading university found that between May 2020 and April 2025, total monthly unit sales in Australia increased from around 58,000 to nearly 497,000, a tenfold rise.
Nearly half of these users, estimated between 180,000 and 240,000 people, are buying the injections directly from pharmacies with no government subsidy. Currently, only individuals with type 2 diabetes are eligible for subsidised access through the Pharmaceutical Benefits Scheme (PBS). This has led to ongoing discussions about whether subsidies should be extended to people with obesity or other related health issues. The study's authors suggest that the actual number of users may be even higher, as their estimates do not account for some of the newer drugs now entering the market, such as Wegovy.
With close to 2% of Australia's population now regularly using these appetite-regulating drugs, the findings raise broader questions about the future of the health system. Medical professionals and policymakers are increasingly concerned about the financial pressure expanded subsidies could place on the PBS, while drug manufacturers continue to lobby for broader access. A federal advisory committee is currently reviewing policy options that could help ensure access for those in need while maintaining financial sustainability.
